Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Drug-induced movement disorders in psychiatric patients: role in the development of treatments

Santiago Perez Lloret, MD, PhD, University of Buenos Aires, Buenos Aires, Argentina, delves into movement disorders caused by antipsychotic drugs, ranging from parkinsonism to dyskinesias. Antipsychotic-induced movement disorders have deepened our understanding of the role of dopamine in generating movement, particularly in the context of Parkinson’s disease. By recognizing that Parkinson’s disease results from a hypodopaminergic tone and the subsequent deficiency of dopamine, researchers have been able to develop treatments like levodopa and dopamine agonists to replace it. Movement, being one of the most observable manifestations of brain function, has served as a crucial bridge between neurology and psychiatry. While dopamine remains a crucial factor in Parkinson’s disease, many unexplored avenues and alterations still demand further investigation. A better understanding of those factors will drive the development of new treatments that could be more effective than the current options. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Honoraria from IPMDS and DNDI. Editor-in-Chief of NDI.